Brain-related Solutions & Services
With advancements in stem cell technology, brain models derived from induced pluripotent stem cells are a powerful tool for research. The ability to differentiate into various cell types such as neural cells, enables us to create three-dimensional models that mimic the structure and functions of the human brain. These brain models are particularly useful in advancing the understanding of neural development and studying neurological diseases.
Brain Organoids
Brain organoids are a miniaturized, in vitro version of the brain that is derived from induced pluripotent stem cells (iPSCs). These organoids are designed to have a similar cellular composition and architecture as the brain, exhibiting similar mechano-physiological. As such, brain organoids are critical tools for researchers developing treatments to neurological diseases, driving different applications such as:
Neurological
Drug Screening +
Neurological
Drug Screening
Organoid-based brain models provide a scalable, high-throughput drug screening assay for drug efficacy and toxicity.
Neurological
Disease Modeling +
Neurological
Disease Modeling
Brain models are an alternative to animal models, providing a more physiologically relevant platform that models diseases such as Parkinson’s and Alzheimer’s.
AAV
Serotype Screening +
AAV
Serotype Screening
Adeno-associated viruses are a critical gene delivery tool. Finding the right serotype for gene transduction into the target tissue type can make or break gene therapies.
Neurodevelopmental
Research +
Neurodevelopmental
Research
Neurodevelopmental research strives to learn about the formation of the nervous system during development, such as generation, migration, connectivity and more.
Brain organoids and differentiation kits are available to support high-throughput differentiation of brain organoids from iPSCs.
Cellular composition including neuron and glial cells with brain-like structures.
Responding to the toxic reactions induced by Pre-formed Fibrils (PFFs).
Immunostaining of 119-day old brain organoid for OLIG2 and TUJ1 reveals the distribution of oligodendroglia and mature neuron cells, respectively.
| Product Type | Cat. No. | Description |
| Brain Organoids | CIPO-BWL001K | Ready-to-use Human iPSC-Derived Cerebral Organoids |
| CIPO-BWL002K | Ready-to-use Human iPSC-Derived Mature Cerebral Organoids 100 days+ | |
| CIPO-MBWL001K | Ready-to-use Human iPSC-Derived Midbrain Organoids | |
| CIPO-BWL001KC | Cryopreserved Human iPSC-Derived Cerebral Organoids | |
| RIPO-BWM003 | Human iPSC-Derived Cerebral Organoid Maturation and Maintenance Kit | |
| Customized Organoids | CIPO-SBWL001K | Ready-to-use Human iPSC-Derived Spinal Cord Organoids |
| CIPO-BVWL001K | Ready-to-use Human iPSC-Derived Vascularized Cerebral Organoids |
Neural Cells
Neural progenitor cells are the progenitor cells that develop into glial and neuronal cells that populate the central nervous system. They possess the ability to self-renew and secrete neurotrophic factors that are crucial in promoting neural regeneration.
Neural progenitor cells are the progenitor cells that develop into glial and neuronal cells that populate the central nervous system. They possess the ability to self-renew and secrete neurotrophic factors that are crucial in promoting neural regeneration.
Neural Cells Product List
Brain Services
Organoid Differentiation and Validation Services
We offer differentiation services to develop brain organoids from iPSCs or human tissue. Organoids are validated by the expression of brain-related protein markers to ensure differentiation and maturity.
Validation by WB, IF, qPCR for MAP2，TH and Morphological evidence
Raw data and images
Detailed validation test report
Brain Toxicity Studies
We can measure the inhibitory effect of electrical signals blocking drugs and the cell viability of neuron cells to better predict drug cerebral toxicity.
Electrophysiological test (2D/3D)，Calcium imaging and patch clamp analysis
Raw data and images
AD / PD Disease Modeling
We can help to construct the AD/PD model with PFFs and provide corresponding pathological findings and biochemical evidence. At the same time, we can also provide you with follow-up drug screening services.
Validation Methods include WB, IF, qPCR for Aβ，pTau，α-Syn, etc. MEA is performed for viability and pathological characterization for validation.
Detailed validation test report
Customed AD/PD model based on organoid
Vascularized Brain Organoids and Blood–brain barrier (BBB)-on-a-chip are coming soon!
Interested? Leave a message!
Brain Case Studies
Alzheimer’s Disease Modeling – Detection of Neural Cells
Developed using our organoid differentiation kit, 55-day old cerebral organoids derived from iPSCs were incubated with varying concentrations of Tau pre-formed fibrils. Anti-pTau antibodies were used to visualize Tau aggregation alongside MAP2 staining to visualize mature neurons.
Aggregation of Tau was visualized in organoids incubated with Tau pre-formed fibrils, represented by the thickening of lines in red. Increasing concentration of PFFs resulted in a more noticeable aggregation of Tau.
Parkinson’s Disease Modeling – Detection of Neural Cells
Developed using our organoid differentiation kit, cerebral organoids derived from iPSCs were incubated with varying concentrations of α-synuclein pre-formed fibrils. TH staining was used to visualize dopaminergic neurons, with MAP2 representing mature neurons.
With the addition of α-syn PFFs into the organoid model, swelling of axon microtubules and neuron density loss is visualized. In comparison to control, significant microtubule loss (thin green lines) suggests oxidative stress stemming from addition of PFFs.
AAV Screening with Brain Organoids
Several AAV serotypes were utilized to evaluate transgene efficacy using cerebral organoid models. Evaluation of the resulting expression of delivered GFP transgene was compared to evaluate transduction and select the optimal AAV serotype in comparison to commercial wild-type AAVs. Cerebral organoids grown for 101 days were infected with 1E+11 μg of AAV5-WT (left), IVB-1 (middle), and IVB-2 (right).
The IVB-2 subtype showed a significantly higher level of infectiousness revealed by the high levels of GFP expression in cerebral organoids.
Drug Toxicity Assessment with Brain Organoids
NMDA is a glutamate receptor agonist that activates the key excitatory NMDA receptors in the brain. Overactivation of these receptors leads to increased calcium influx, resulting in excitatory toxicity, which causes neuronal damage or even death. Cerebral Organoids were treated with increasing concentrations of NMDA to assess excitotoxicity.
NMDA induced dose-dependent cell damage, as demonstrated by reduced numbers of neurons (MAP2+) and neural stem cells (SOX2+), along with increased Caspase-3 activity (an apoptosis marker) and LDH release (an indicator of membrane damage and cytotoxicity). Compared to 2D-cultured SH-SY5Y cells, cerebral organoids exhibited greater resistance to excitotoxic stress.
Related Recommendations
References
1. Hernandez-Baltazar, Daniel, et al. "Animal model of Parkinson disease: Neuroinflammation and apoptosis in the 6-hydroxydopamine-induced model." Experimental Animal Models of Human Diseases [Internet]. Rijeka: InTech (2018): 375-393.
2. Chongyuan Luo, et al. Cerebral Organoids Recapitulate Epigenomic Signatures of the Human Fetal Brain. VOLUME 17, ISSUE 12, P3369-3384, DECEMBER 20, 2016.
- Background
- Brain Organoids
- Neural Cells
- Neural Cells Product List
- Brain Services
- Brain Case Studies
- Related Recommendations
- References